Humanigen Inc. (HGEN) Announces NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
- Indexes close up more than 1% as investors assess Fed news
- China Tells Local Authorities to Prepare For a 'Possible Storm' and Prevent Unrest as Evergrande Crisis Unravels - WSJ
- Salesforce (CRM) Raises FY22 Revenue Guidance; Initiates FY23 Revenue
- Oil prices rise, hit 2-month highs on supply worries
- IDFA Seen as a 'Real Headwind' for Facebook (FB) but Analysts Remain Positive
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company developing a first-in-class GM-CSF neutralizing antibody to prevent and treat an immune hyper-response called ‘cytokine storm’ across multiple therapeutic indications, has announced that the NIH has advanced the ACTIV-5/BET-B study to a Phase 2/3 study and modified the primary endpoint to survival without ventilation (“SWOV”), the same endpoint used in the Phase 3 LIVE-AIR study.
The amended ACTIV-5/BET-B study now includes 400 patients overall. Up to sixty US sites will be participating in the study. Humanigen is providing lenzilumab and assisting the NIH to achieve the timely completion of the study. NIH is sponsoring and funding this study.
“We appreciate the close collaboration with NIH on this important study,” said Adrian Kilcoyne, MD, Chief Medical Officer, Humanigen. “The ACTIV-5/BET-B study design has been adapted to align with the design of LIVE-AIR and may help support a future BLA for lenzilumab.”
“Sharing the same endpoint as the LIVE-AIR study, the ACTIV-5/BET-B study reinforces the potential for lenzilumab to treat hospitalized COVID-19 patients,” said Vincent Marconi, MD, Professor of Medicine at Emory University School of Medicine. “At Emory University, a key center in both the LIVE-AIR and ACTIV-5/BET-B studies, we believe these trials can identify the optimal patient population for lenzilumab. LIVE-AIR showed us that COVID-19 patients who at baseline had a CRP of less than 150 mg/L and are under 85 years of age had the greatest response to lenzilumab. Using CRP as a biomarker to identify COVID-19 patients at risk for disease progression, in whom lenzilumab treatment can be initiated prior to full blown cytokine storm, would be lifesaving.”
“ACTIV-5/BET-B may provide prospective validation for lenzilumab in the treatment of COVID-19,” said Cameron Durrant, MD, Chief Executive Officer, Humanigen. “We believe ACTIV-5/BET-B, along with LIVE-AIR, will provide the sufficient size and statistical power typically required for a BLA to be submitted to FDA.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- vTv Therapeutics (VTVT) Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
- Twist Bioscience Corporation (TWST) Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of COVID-19
- Pfizer (PFE) and BioNTech SE (BNTX) Announce FDA Emergency Use Authorization of COVID-19 Vaccine Booster
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!